Business Wire

BearingPoint Elects Stefan Penthin to Be the Next Managing Partner of the Global Firm

Share

With, as planned, the final term of its current Managing Partner coming to an end, the partnership of the independent management and technology consultancy, BearingPoint, has elected Stefan Penthin to be its next Managing Partner, effective September 1, 2024. He will succeed Kiumars Hamidian, who successfully headed the business since his appointment in 2018, and did not stand for re-election after two terms in office as planned. The new Managing Partner was elected by the BearingPoint Partners in a collaborative process based on the principle of One Partner - One Vote.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327335930/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Stefan Penthin will be the next worldwide Managing Partner of BearingPoint. (Photo: Business Wire)

Stefan Penthin comments: “I am honored to be entrusted as the next Managing Partner of our firm and am fully committed to the long-term success of our clients and the partnership. We have extraordinary people and a strong portfolio driven by the spirit of innovation and entrepreneurship. We will go further with our mission, creating lasting outcomes for our clients, and enabling people to succeed.”

Stefan Penthin has been with BearingPoint for 23 years and became a Partner in 2012. He is a member of the firm’s global Management Committee and of the German Executive Committee. He is also the global leader for BearingPoint’s market segments as well as the global leader for Automotive & Industrial Manufacturing. Stefan brings more than 25 years of experience in business consulting to the table and has been leading large global consulting projects and business transformation programs with a focus on automotive and manufacturing industries. Stefan’s functional expertise is centered around supply chain management, operational excellence, as well as production and logistics optimization. His clients include major multinational corporations as well as specialized segment players across the globe.

Kiumars Hamidian comments: “Congratulations to Stefan Penthin! With him taking up the role as Managing Partner in September, I know that our business is in the safest possible hands. Stefan is a highly trusted leader and has been exceptionally successful in creating client value, he has excellent abilities, deep industry expertise, and an outstanding commitment to our values and principles. In his role as the global leader for our market segments, Stefan has made a significant contribution to the outstanding business success of our firm with revenues increasing to over EUR 1 billion. The transition process is well on schedule, and fully supported by the entire partnership of our firm.”

Kiumars Hamidian, Managing Partner at BearingPoint since 2018, guided BearingPoint successfully through the pandemic and to new heights. Under his leadership, revenues rose to more than EUR 1 billion and the number of employees increased to more than six thousand in 2023.

During Hamidian’s time in office, 13 acquisitions were delivered, a new subsidiary in India opened, and the US and Asia business expanded. In addition, the first joint venture (Arcwide) has been successfully established, and BearingPoint RegTech and BearingPoint Beyond (today flourishing as independent companies) have been successfully spun off. Moreover, BearingPoint established its purpose “Together, we are more than business,” and embraced a people-centric culture. Once the handover to Stefan Penthin is complete, Kiumars Hamidian will start his official early retirement phase in early 2025.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provide IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com 
LinkedIn: www.linkedin.com/company/bearingpoint 
X: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press

Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye